Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Breast Neoplasms 8Lung Neoplasms 5Colorectal Neoplasms 3Prostatic Neoplasms 2Neoplasm Metastasis 2Melanoma 2Hot Flashes 2Glioblastoma 2Carcinoma, Non-Small-Cell Lung 2COVID-19 2Brain Neoplasms 2Water-Electrolyte Imbalance 1Ventilator-Induced Lung Injury 1Surgical Wound 1Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Severe Acute Respiratory Syndrome 1Rectal Neoplasms 1Postoperative Complications 1Pathologic Complete Response 1Neoplasm, Residual 1Mastocytosis 1Lymphopenia 1Lymphoma, Non-Hodgkin 1Lymphedema 1Lower Urinary Tract Symptoms 1Locally Advanced Head and Neck Squamous Cell Carcinoma 1Leukemia, Myeloid, Acute 1Leukemia, Hairy Cell 1Hypersensitivity 1

Interventions

iniparib 2Poly(ADP-ribose) Polymerase Inhibitors 2amminedichloro(2-methylpyridine)platinum(II) 1ZD4054 1Sodium Chloride 1Rituximab 1Paclitaxel 1Carboplatin 1BNT162 Vaccine 12019-nCoV Vaccine mRNA-1273 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Hypersensitivity × Sodium Chloride × Clear all
NCT04761822 2025-08-12

SARS

National Institute of Allergy and Infectious Diseases (NIAID)

Phase 2 Completed
746 enrolled 28 charts
Myeloid

COVID-19, Hypersensitivity, Mastocytosis, Severe Acute Respiratory Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡